Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: A LIFE substudy

Journal of Hypertension

Volumn 23, Issue 5, 2005, Pages 1083-1090

  Olsen, Michael Hecht ^a   Wachtell, Kristian ^a   Tuxen, Christian ^b   Fossum, Eigil ^c   Bang, Lia E ^a   Hall, Christian ^d   Ibsen, Hans ^a   Rokkedal, Jens ^a   Devereux, Richard B ^e   Hildebrandt, Per R ^b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adrenergic beta receptor blockers; Angiotensin II receptor antagonists; Hypertension; Left ventricular hypertrophy; Natriuretic peptides; Nt proANP; Nt proBNP

Indexed keywords

ATENOLOL; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; LOSARTAN; NATRIURETIC FACTOR;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HUMAN; HYPERTENSION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 21044442679     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000166851.18463.85     Document Type: Article

References (33)

1. Ballermann BJ, Brenner BM, George E. Brown memorial lecture. Role of atrial peptides in body fluid homeostasis. Circ Res 1986; 58:619-630.
2. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38:1934-1941.
3. Hall C, Rouleau JL, Moye L, de Champlain J, Bichet D, Klein M, et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994; 89:1934-1942.
4. Olsen MH, Wachtell K, Tuxen C, Possum E, Bang LE, Hail C, et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004; 22:1597-1604.
5. McDonagh TA, Cunningham AD, Morrison CE, McMurray JJ, Ford I, Morton JJ, et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001; 86:21-26.
6. Raizada V, Thakore K, Luo W, McGuire PG. Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem 2001; 216:137-140.
7. Sundsfjord JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 1988; 66:605-610.
8. Qi W, Mathisen P, Kjekshus J, Simonsen S, Bjornerheim R, Endresen K, et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 2001; 142:725-732.
9. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126-1130.
10. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87:464-469.
11. Kohno M, Horio T, Yokokawa K, Yasunari K, Ikeda M, Minami M, et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med 1995; 98:257-265.
12. Kohno M, Minami M, Kano H, Yasunari K, Maeda K, Hanehira T, et al. Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left venticular hypertrophy. Metabolism 2000; 49:1356-1360.
13. Kohno M, Yokokawa K, Yasunari K, Kano H, Minami M, Hanehira T, et al. Changes in plasma cardiac natriuretic peptides concentrations during 1 year treatment with angiotensin-converting enzyme inhibitor in elderly hypertensive patients with left ventricular hypertrophy. Int J Clin Pharmacol Ther 1997; 35:38-42.
14. Focaccio A, Volpe M, Ambrosio G, Lembo G, Pannain S, Rubattu S, et al. Angiotensin II directly stimulates release of atrial natriuretic factor in isolated rabbit hearts. Circulation 1993; 87:192-198.
15. Tunny TJ, Bachmann AW, Gordon RD. Response of atrial natriuretic peptide to adrenaline and noradrenaline infusion in man. Clin Exp Pharmacol Physiol 1988; 15:299-303.
16. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study [In Process Citation]. Hypertension 1998; 32:989-997.
17. Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001; 10:74-82.
18. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994; 23:1444-1451.
19. Dahlof B, Devereux RB, Kjeidsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
20. Nguyen PV, Smith DL, Leenen FH. Acute volume loading, atrial natriuretic peptide release and cardiac function in healthy men. Effects of beta-blockade. Life Sci 1988; 43:821-830.
21. Luchner A, Burnett JCJ, Jougasaki M, Hense HW, Riegger GA, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 1998; 32:1839-1844.
22. Omvik P, Lund-Johansen P, Myking O. Effects of carvedilol on atrial natriuretic peptide, catecholamines, and hemodynamics in hypertension at rest and during exercise. J Cardiovasc Pharmacol 1992; 19(suppl 1): S90-S96.
23. Tanaka M, Ishizaka Y, Ishiyama Y, Kato J, Kida O, Kitamura K, et al. Chronic effect of beta-adrenoceptor blockade on plasma levels of brain natriuretic peptide during exercise in essential hypertension. Hypertens Res 1996; 19:239-245.
24. Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20:1855-1864.
25. Elijovich F, Laffer CL, Schiffrin EL. The effects of atenolol and zofenopril on plasma atrial natriuretic peptide are due to their interactions with target organ damage of essential hypertensive patients. J Hum Hypertens 1997; 11:313-319.
26. van den Meiracker AH, Lameris TW, van de Ven LL, Boomsma F. Increased plasma concentration of natriuretic peptides by selective beta1-blocker bisoprolol. J Cardiovasc Pharmacol 2003; 42:462-468.
27. Groenning BA, Nilsson JC, Sondergaard L, Kjaer A, Larsson HB, Hildebrandt PR. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail 2001; 3:699-708.
28. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110:1456-1462.
29. Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 2002; 25:669-676.
30. Fung J W, Yu CM, Yip G, Chan S, Yandle TG, Richards AM, et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003; 92:406-410.
31. Gabrielli O, Puyo AM, De Rosa A, Armando I, Barontini M, Levin G. Atenolol improves ventricular function without changing plasma noradrenaline but decreasing plasma atrial natriuretic factor in chronic heart failure. Auton Autacoid Pharmacol 2002; 22:261-268.
32. Ogawa T, Linz W, Stevenson M, Bruneau BG, Kuroski dBM, Chen JH, et al. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation 1996; 93:2059-2067.
33. Klinge R, Polis A, Dickstein K, Hall C. Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure. J Card Fail 1997; 3:75-81.